Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119799 | 1.00 | EPHX2 (0.45) | EPHX2TRPV1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4119812 | 0.93 | EPHX2 (0.51) | EPHX2TRPV1LMNAHTTMTOR | |
| SCHEMBL4119809 | 0.93 | EPHX2 (0.51) | EPHX2TRPV1LMNAHTTMTOR | |
| SCHEMBL4112937 | 0.91 | KMT2A (0.49) | LMNAHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4112935 | 0.91 | KMT2A (0.49) | LMNAHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4114912 | 0.88 | MEN1 (0.48) | EPHX2TRPV1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4114916 | 0.88 | MEN1 (0.48) | EPHX2TRPV1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4110161 | 0.88 | MEN1 (0.48) | EPHX2TRPV1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4110158 | 0.88 | MEN1 (0.48) | EPHX2TRPV1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4109459 | 0.87 | CNR2 (0.51) | EPHX2TRPV1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546452-B2 | S1P3 receptor antagonist | TOA EIYO LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20090170895-A1 | S1P3 RECEPTOR ANTAGONIST | TOA EIYO LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1935874-A1 | S1P3 RECEPTOR ANTAGONIST | TOA EIYO LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170895-A1 | S1P3 RECEPTOR ANTAGONIST | S1PR3, S1PR5, GPR3 | EPHX2 2154/4885TRPV1 165/4885LMNA 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.